Corneal Changes in Estrogen-Dependent Breast Cancer After Hormonal Treatment (breast cancer)

Sohag University

Status and phase: Completed; Phase 4

Conditions: Dry Eye; Braest Cancer

Treatments: Drug: Hormonal treatment

Study type: Interventional

Funder types: Other

Identifiers

NCT06924229

Soh-Med-24-03-14PD

Details and patient eligibility

About

Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment.

Full description

Aromatase inhibitors (AI) therapy is an important treatment for estrogen receptor-positive breast cancer (BC). This work evaluated the eye anterior segment changes in estrogen-dependent BC after hormonal treatment.

This cross-sectional study was conducted on female patients aged ≥18 who received treatment for BC. Patients were evaluated by a number of tests to determine the effects on the cornea and the lacrimal system

Enrollment: 40 patients

Sex: Male

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females diagnosed with breast cancer

Exclusion criteria

• uncontrolled diabetes , auto immune diseases

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

40 participants in 1 patient group

patients with breast cancer recieving hormonal treatment

Active Comparator group

Description:

evaluation of the effect of hormonal treatment on the cornea

Treatment:

Drug: Hormonal treatment